SCHEMBL4297016

SCHEMBL4297016

CN(C)C(=O)c1cccc(NC(=O)COc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.66
TP53 P04637 3/20 0.66
LMNA P02545 2/20 0.66
MEN1 O00255 6/20 0.61
KMT2A Q03164 6/20 0.61
MAPT P10636 9/20 0.58
NPC1 O15118 3/20 0.58
HPGD P15428 4/20 0.57
HTT P42858 2/20 0.57
ALDH1A1 P00352 2/20 0.57
GAA P10253 1/20 0.57
THRB P10828 1/20 0.57
ALOX12 P18054 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.54
PTGES O14684 1/20 0.54
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP3A4 P08684 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
PKM P14618 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4296021 0.86 MEN1 (0.63) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4298332 0.86 RAB9A (0.63) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4295572 0.86 RAB9A (0.63) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4298335 0.85 MEN1 (0.61) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4297524 0.85 MEN1 (0.61) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL12218388 0.84 MAPT (0.72) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4304244 0.83 KMT2A (0.60) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL18327156 0.82 MAPT (0.79) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4302330 0.81 RAB9A (0.64) RAB9ATP53LMNAMEN1KMT2A
SCHEMBL4296024 0.81 MEN1 (0.65) RAB9ATP53LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US claimed
US-8394799-B2 Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2013-03-12 US disclosed
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US disclosed
WO-2008004798-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT HIF1AN, HIF1A, VHL RAB9A 884/4885TP53 274/4885LMNA 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.